Table 1.
Compilation of the studies selected for the current review.
| ENP Type | Customization (Targeting Ligand) | Therapeutics | Route of Administration and Animal Model | Reference |
|---|---|---|---|---|
| polyethylene gycol–polylactide–polyglycolide (PEG-PLGA) | Lactoferrin (Lf) targeting the Transferrin Receptor (TfR) on endothelial cells | Urocortin (URO) | Intravenous (IV) Rat model of Parkinson’s disease (PD) |
[40] |
| PEG-PLGA | Lactoferrin (Lf) targeting the TfR on endothelial cells | Shikonin (SHK) | IV Healthy rats only |
[41] |
| PLGA | Non applicable (NA) | Curcumin (Cur) | Intraperitoneal (IP) Rat model of Alzheimer’s disease (AD) |
[42] |
| Tripolyphosphate cross-linked cationic chitosan (CS) | NA | Piperine (PIP) | Intranasal (IN) Rat model of sporadic dementia of AD type |
[43] |
| Nanostructured Lipid Carrier (NLC) coated with cationic CS | TransActivator of Transcription (TAT) | Glial cell-Derived Neurotrophic Factor (GDNF) | IN Mouse model of PD |
[44] |
| cationic nanoliposomes (scL) | Single-chain fragment from the variable region of anti-TfR monoclonal antibody (TfRscFv) | siRNA against TNFα | IV Lipopolysaccharide (LPS)-induced neuro-inflammation in mice |
[45] |
| PEG polymeric poly lactic acid (PLA) | Cationic bovine serum albumin (CBSA) | Tanshinone IIA (TIIA) | Rat model of cerebral ischemic stroke | [46] |
| PEG-PLGA | Odorranalectin (OL), targeting l-fucose expressed on the olfactory epithelium | URO | IN Rat model of PD |
[47] |
| Cationic lipids nanoemulsions (SNE) | NA | siRNA against TNFα | IN LPS-induced neuro-inflammation in rats |
[48] |
| Poly-Butyl-CyanoAcrylate (PBCA) | Non-ionic surfactants (in particular Tween 80) with or without cationic resin DEAE (both interacting with circulating apoliproprotein E) | NA | IV Healthy rats only |
[49] |
| Gold nanoparticles (GNP) | Insulin (INS) | NA | IV Healthy mice only |
[53] |
| CS-PEG | Anti-TfR monoclonal antibody OX26 | NA | IP Healthy mice only |
[54] |